MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$196.01M

FY 2025 · Annual

Investing Cash Flow

$202.99M

FY 2025 · Annual

Financing Cash Flow

$146.00M

FY 2025 · Annual

+184.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(53.64M)(49.97M)(44.08M)(121.24M)(229.1M)
Depreciation & Amortization4.97K12.36K13.16K1.38M2.62M
Deferred Income Tax00000
Stock-Based Compensation10.86M9.65M7.11M7.28M12.9M
Change in Working Capital4.48M(1.43M)(6.22M)(3.78M)19.88M
Accounts Receivables(148.77K)(68.36K)(840K)(1.79M)(2.03M)
Inventory00000
Accounts Payables1.57M(1.31M)000
Other Working Capital3.06M(44.8K)(6.22M)(2M)21.9M
Other Non-Cash Items13.98M(4.51M)399.51K(225.71K)(2.3M)
Operating Cash Flow(35.18M)(55.89M)(42.78M)(116.59M)(196.01M)
Capital Expenditures(50.71K)(16.01K)(284.63K)(519.52K)(35K)
Acquisitions (Net)00000
Purchases of Investments0(42.23M)(175.73M)(350.28M)(265.37M)
Sales of Investments09.9M150.83M145.2M468.4M
Other Investing Activities00000
Investing Cash Flow(50.71K)(32.34M)(25.18M)(205.6M)202.99M
Debt Repayment15M(15M)0073.02M
Common Stock Issued28.27M3.79K482.45M52.54M72.98M
Common Stock Repurchased(6.2K)00(50)0
Dividends Paid00000
Other Financing Activities0134.69M(2.75M)(1.23M)0
Financing Cash Flow43.26M119.69M479.7M51.31M146M
Effect of Forex Changes(1.33M)8.54K(75.31K)127.97K1.11M
Net Change in Cash6.7M31.47M411.66M(270.74M)154.09M
Free Cash Flow(35.23M)(55.91M)(43.06M)(117.11M)(196.04M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$229.1M
+ D&A$2.6M
+ Stock-Based Comp$12.9M
+ Deferred Tax$0
+ Working Capital$19.9M
- Other Non-Cash-$2.3M
= Operating Cash Flow-$196.0M
- Capex-$35.0K
= Free Cash Flow-$196.0M

Analysis

FY2025 free cash flow is -$196.0M. FCF conversion is 85.6% of net income. Operating cash flow was -$196.0M, with capex of -$35.0K. The largest bridge item is Working Capital at $19.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportSep 30, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13GSC 13G filingAug 14, 2026

Does MLTX generate free cash flow?

MoonLake Immunotherapeutics (MLTX) generated -$196.04M of free cash flow in fiscal 2025.

How much operating cash flow does MLTX produce?

Operating cash flow was -$196.01M, before capital expenditures of $35,000.00.